Significant variability in the antitumor efficacy and systemic toxicity of gemcitabine has been observed in cancer patients. However, there are currently no tools for prospective identification of patients at risk for untoward events. This study has identified and validated single-nucleotide polymorphisms (SNP) in genes involved in gemcitabine metabolism and transport. Database mining was conducted to identify SNPs in 14 genes involved in gemcitabine metabolism. Pyrosequencing was utilized to determine the SNP allele frequencies in genomic DNA from European and African populations (n ¼ 190). A total of 14 genetic variants (including 12 SNPs) were identified in eight of the gemcitabine metabolic pathway genes. The majority of the database variants were observed in population samples. Nine of the 14 (64%) polymorphisms analyzed have allele frequencies that were found to be significantly different between the European and African populations (Po0.05). This study provides the first step to identify markers for predicting variability in gemcitabine response and toxicity.
INTRODUCTION
Gemcitabine (2 0 ,2 0 -difluorodeoxycytidine, dFdC) is a deoxycytidine analog that has demonstrated anticancer activity in several solid tumors, including pancreatic, lung and breast cancer. [1] [2] [3] [4] [5] [6] [7] Gemcitabine has a complex metabolic pathway ( Figure 1 ). [8] [9] [10] There are many mechanisms that can contribute to gemcitabine cytotoxicity. Gemcitabine is transported into the cell by nucleoside transporters. 11, 12 Once gemcitabine has entered the cell, it must be phosphorylated to the active metabolite 2 0 ,2 0 -difluorodeoxycytidine triphosphate (dFdCTP). Gemcitabine phosphorylation is catalyzed by deoxycytidine kinase (DCK) into the monophosphate metabolite, difluorodeoxycytidine monophosphate (dFdCMP). 11, 13 dFdCMP can be incorporated into DNA; this metabolite inhibits the exonuclease activity of DNA polymerase e (POLE), allowing the damaged DNA strand to remain unrepaired. 10, 14 The monophosphorylated metabolite is subsequently phosphorylated to difluorodeoxycytidine diphosphate (dFdCDP) and dFdCTP by nucleoside monophosphate and nucleoside diphosphate kinases, respectively. 12 Once dFdCDP is formed, it can inhibit ribonucleotide reductase. The inhibition of ribonucleotide reductase causes a decrease in deoxycytidine triphosphate (dCTP). Endogenous dCTP stimulates deoxycytidine monophosphate deaminase (DCTD), which is responsible for the breakdown of dFdCMP to difluorodeoxyuridine monophosphate (dFdUMP). 15 Consequently, this decrease in endogenous dCTP reduces the catabolism of gemcitabine. Additionally, decreasing the amount of dCTP downregulates feedback inhibition of DCK, leading to an increase in gemcitabine phosphorylation to dFdCTP. [16] [17] [18] Increased intracellular concentrations of dFdCTP can inhibit dCMP deaminase and decrease the catabolism of dFdCMP, allowing for the self-potentiation of dFdC cytotoxic activity. 10 The deamination product of dFdCMP, dFdUMP, inhibits thymidylate synthase (TS). Inhibition of TS activity is associated with an increase in DNA synthesis errors leading to DNA damage. 19, 20 Similarly, there are several factors that may contribute to gemcitabine resistance. Increased activity of cytidine deaminase (CDA) can increase the breakdown of gemcitabine before it enters the cell. 21, 22 Nonfunctional nucleoside transporters can also play a role in gemcitabine resistance. If gemcitabine is not transported into the cell, gemcitabine cannot inhibit cell growth. 12, 23, 24 A deficiency in DCK can confer resistance to gemcitabine, by decreasing gemcitabine phosphorylation. 25 Another factor of gemcitabine resistance is the overexpression of ribonucleotide reductase, which causes an increase in dCTP. An increase in dCTP will increase feedback inhibition of DCK, thereby decreasing phosphorylation of gemcitabine. Additionally, increased dCTP pools can cause increased expression of DCTD, leading to increased catabolism and clearance of gemcitabine. 9, 26 Owing to the broad antitumor activity of gemcitabine, it is essential to gain a better understanding of the mechanisms of de novo activation and resistance for gemcitabine. One way to begin to broaden our understanding of gemcitabine metabolism is to examine the genetic differences in the metabolic enzymes, potentially explaining differences in response to gemcitabine. [2] [3] [4] [5] [6] [7] Currently, there is a focus on analyzing individual genes that may be involved in drug metabolism. It is unlikely that a single gene will be the key to understanding inter-patient variability. In this study, we aimed to focus on multiple components of the gemcitabine metabolism pathway. 4 
RESULTS
A total of 14 genetic variants were discovered among the 13 gemcitabine metabolic pathway genes. 4 No database polymorphisms were identified for SLC29A2, UMP-CMPK, POLE, RRM1 or RRM2. Three single-nucleotide polymorphisms were identified in the CDA gene. One SNP, CDA 435C4T, Figure 1 Gemcitabine pharmacologic pathway representing drug transport, metabolism and cellular targets. Genes in bold were evaluated in this investigation. Official Human Genome Organization (HUGO) nomenclature is used. Common or alternative names for these genes may be found at http://pharmacogenetics.wustl.edu.
Gemcitabine pharmacologic pathway SNPs AK Fukunaga et al did not encode for an amino-acid change. CDA 79 A4C encoded for a lysine to glutamine amino-acid change (K27Q) and the SNP published by Yue et al, CDA 208G4A, encodes for an alanine to threonine amino-acid change (A70T). 27 The two SNPs identified in the DCK gene, DCK IVS1-1110T4C and DCK 2190A4T, did not encode for an amino-acid substitution. A synonymous (T4C) SNP at nucleotide 315 was reported in the DCTD gene. A nonsynonymous SNP was identified in POLA2, which encoded for a glycine to arginine (G583R) amino-acid change. Five SNPs were identified in the nucleotide transporter genes. SLC28A1 1383C4T and SLC29A1 778G4A did not encode for an amino-acid substitution. SLC28A2 283A4C encodes for an arginine to serine change (R75S), SLC28A1 1576T4C encodes for an asparagine to aspartic acid (N521D) aminoacid change and SLC28A1 1543G4A encodes for an arginine to cysteine (R510C) amino-acid change. Lastly, a 3 0 UTR deletion in the TYMS gene was identified by Ulrich et al 28 and a TYMS enhancer region repeat was previously analyzed in the population samples used in this study by Marsh et al.
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Of the 14 gemcitabine pathway variants, 12 were observed in the general population samples (Table 1a and b). All genotype frequencies were in Hardy-Weinberg equilibrium. SNPs reported in the SLC29A1 778G4A and DCK IVS1-1110 T4C could not be validated in this investigation, as no variants were observed in either the African and European populations. The genotype frequencies for nine of the 14 polymorphisms were significantly different (Po0.05) between the African and European populations (Table 1) .
Four genes had more than one genetic variant-CDA, DCK, SLC28A1 and TYMS. Analysis using the Polymorphism and Haplotype Analysis Suite 30 revealed that no significant linkage disequilibrium existed between polymorphisms within CDA, DCK, SLC28A1 and TYMS (P40.05).
Six SNPs (CDA 79A4C, CDA 208G4A, POLA2 2089G4A, SLC28A1 1543G4A, SLC28A1 1576T4C and SLC28A2 283A4C) encoded for an amino-acid change. CDA 208G4A encodes for a hydrophobic amino acid (alanine) to a hydrophilic amino acid substitution (threonine). For CDA 79A4C, CDA 208G4A, POLA2 2089G4A, SLC28A1 1576T4C and SLC28A2 283 A4C, neither NNPREDICT 31 nor GOR IV 32 revealed any theoretical differences in secondary protein structure with the amino-acid substitutions. In contrast, both prediction methods suggested that the amino-acid substitution from arginine to cysteine observed in SLC28A1 1543G4A would perturb the predicted helical structure at this position, which could possibly affect its membrane transporter activity.
Using the SPDB Viewer (http://us.expasy.org/spdbv/, PDB ID code 1CTU) to evaluate CDA 208G4A, the proximity of this amino-acid substitution to the active site of this protein may affect the activity of CDA by influencing the packing of the helix in which it resides. 33 The N-terminus of the helix in which this residue resides forms an important area of the active site of CDA. The substitution of threonine for alanine at this position may influence the overall position of this alpha helix as the structure adapts to the presence of the larger side chain and thus influences the activity of the enzyme.
DISCUSSION
Cancer chemotherapy agents often demonstrate variation in drug response and toxicity between individuals. 34, 35 Singlenucleotide polymorphisms in drug-metabolizing enzymes can explain some of the differences in clinical outcomes. 36 This investigation identified 14 polymorphisms in the enzymes responsible for metabolizing gemcitabine, of which 12 were validated to occur in European or African populations. There have been no published evaluations of gemcitabine toxicity or efficacy within ethnic or racial groups. However, differences in survival for lung, breast and pancreatic cancer have been described between racial groups, even when standardized by stage of disease. 37, 38 A greater understanding of the relationship between singlenucleotide polymorphisms and their impact on gemcitabine clinical outcome would be of particular interest to the European populations because there is a greater incidence of breast, lung and pancreatic cancers in European countries than in Africa. 39 Further functional analysis of these polymorphisms is needed to determine their clinical implications in gemcitabine therapy.
Functional impact of SNPs on ara-C toxicity has been observed in a study by Yue et al. The authors report that there is a difference in functional enzyme activity between the wild type and variant CDA 208 G4A. 27 Ara-C is another deoxycytidine analog that utilizes many of the same metabolic enzymes as gemcitabine. Yeast expression systems revealed that CDA 208 G4A had a significantly lower ara-C IC 50 value. 27 In the current investigation, it was determined that CDA 208 G4A and CDA 79 A4C had significantly different genotype frequencies, between the African (q ¼ 0.125 and q ¼ 0.965, respectively) and European populations (q ¼ 0.0 and q ¼ 0.363, respectively). Additionally, protein modeling of CDA 208 G4A suggests that the amino-acid change may lead to a change in protein conformation near the active site. The finding by Yue et al suggests that a population of people carrying the CDA 208 G4A allele could be more sensitive to gemcitabine treatment. This is of particular interest to African populations as over 12% of the African population in this study had at least one copy of the variant allele.
Osato et al 40 recently described the haplotype structure of SLC29A1 and performed functional analysis of two nonsynonymous variants of SLC29A1. They summarized the allele frequencies of 15 SNPS in SLC29A1, which did not include the SLC29A1 778G4A SNP investigated in this study. In yeast expression systems, neither of the nonsynonymous SNPs (I216T, E391K) had an apparent effect on SLC29A1-mediated transport, when compared with the reference transporter. In addition, they determined that the competitive inhibition of Further investigation of other variants in SLC29A1 is needed to determine if the variants may play an important role in the differences in clinical response to nucleotide analog drugs, like gemcitabine. Additionally, studies of the SLC29A1 variants in mammalian systems are required to delineate the true relationship of the variant transporters and their effect on interindividual variation in drug response.
Two TYMS polymorphisms were included in this study, a 28 bp repeat in the enhancer region of this gene and a 6 base pair deletion in the 3 0 UTR. 29, 40 Further investigation of the repeat polymorphism in the enhancer region would be of interest, because it has been shown that colorectal cancer patients treated with 5FU with the TSER*3/TSER*3 genotype have lower survival rate compared to those patients with the TSER*3/TSER*2 or TSER*2/TSER*2 genotypes. 41 Additionally, the deletion polymorphism is located in the 3 0 untranslated region of TYMS, which could affect mRNA stability and possibly affect the expression of this gene. Preliminary data have suggested that the absence of the 6 bp significantly reduces TYMS mRNA expression in colorectal cancer patients. 42 Currently, the investigations by Yue et al 27 and Osato et al 40 are the only studies to have evaluated the impact of genetic polymorphism on the functional activity of an enzyme involved in gemcitabine metabolism. As reported in this investigation, there are 12 SNPs, one deletion and one repeat polymorphism present in the public databases among the gemcitabine metabolic pathway genes, including nine which display significantly different genotype frequencies between the African and European populations. With the increasing number of SNP mining and gene resequencing projects currently underway, it is likely that many more polymorphisms will be found in these genes in the near future. Additional studies of functional differences of these and novel SNPs are essential to gain insight into the variable gemcitabine response between individuals.
Individual variability in drug response in the context of a complex pathway such as gemcitabine is unlikely to be caused by one polymorphism in one gene. To date, little focus has been placed on global analysis of metabolic pathway genes to determine the effects of combinations of gene variants on drug response. The goal of this study was to identify and validate the database polymorphisms found in the gemcitabine metabolic pathway. Identifying, validating and analyzing the differences in allele frequencies of these polymorphisms provides a starting point for investigating the relationship between SNPs found in the gemcitabine metabolic pathway and the possible effect on clinical outcome. Functional analysis of these polymorphisms in an in vivo system is an essential next step to help gain a better understanding of gemcitabine pharmacokinetics and lead to optimized gemcitabine therapy.
MATERIALS AND METHODS

SNP Discovery
SNPs were identified using publicly available SNP databases ( Table 2) . 43 GeneCards (http://bioinformatics.weizmann.ac.il/cards/) and OMIM (http://www3.ncbi.nlm.nih.gov/ Omim) databases were utilized to gain information on the genes in the gemcitabine metabolic enzymes. Database queries for SNPs in the gemcitabine metabolic pathway were conducted in CGAP (http://lpgws.nci.nih.gov/perl/ snpbr), LEELAB (http://www.bioinformatics.ucla.edu/snp/), HGVBase (http://hgvbase.cgb.ki.se/), and HOWDY (http:// gdb.jst.go.jp/HOWDY/) (which includes dbSNP (http:// www.ncbi.nlm.nih.gov/SNP/) and JSNP (http://snp.ims.utokyo.ac.jp/)). The CDA A70T substitution at nucleotide 208 was also previously described by Yue et al. 27 The 5 0 repeat polymorphism and 3 0 UTR deletion in the TYMS gene were previously validated in a study by Ulrich et al 28 and Marsh et al.
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Population Samples Genomic DNA from 95 European and 95 African healthy unrelated blood donors was obtained as previously described. 44, 45 The genomic DNA was analyzed for the 14 polymorphisms in the gemcitabine metabolic pathway. This study was approved by the Washington University Human Subjects Committee. (Table 2) were designed using Primer Express Version 1.5. (ABI, Foster City, CA, USA) for the amplification of the 12 SNPs in the gemcitabine metabolic pathway (Table 3) . PCR was carried out in a 20 ml reaction using Amplitaq Gold PCR mastermix (ABI, Foster City, CA, USA), 5 pmol of forward and reverse primers (IDT, Coralville, IA, USA) and 10-50 ng of genomic DNA. The reaction conditions included 20 min at 931C for activation of Taq polymerase, followed by 55 cycles of 30 s at 951C, 30 s at the appropriate annealing temperature (Table 2 ), and 30 s at 721C, and by a final 5 min extension at 721C.
Pyrosequencing PCR products were incubated with streptavidin magnetic beads (Dynal AS, Oslo, Norway) and a 2 Â binding wash buffer (10 mM Tris-HCl, 2 M NaCl, 1 mM EDTA, 0.1% Tween 20) at 1400 RPM for 15 min at 651C on an Eppendorf Thermomixer R (Brinkmann, Westbury, NY, USA). The PCR product was then denatured by a 1-min incubation in 0.5 M NaOH solution and washed in annealing buffer (20 mM Tris-acetate, 5 mM Mg(OAc) 2 ). The single-stranded products were transferred to an annealing buffer containing 15 pmol of the internal primer (IDT, Coralville, IA, USA) ( Table 2 ) and incubated for 2 min at 801C. Genotyping of the SNPs was performed and analyzed on a PSQ96 pyrosequencer and PSQ 96MA software (Pyrosequencing AB, Uppsala, Sweden).
Protein Conformation
The SNPs that had significantly different allele frequencies between populations, and encoded for an amino-acid change, were subjected to predictive analysis to reveal theoretical changes to secondary protein structure. Prediction analysis was performed using NNPREDICT 31 and GOR IV. 32 Three-dimensional protein structure was visually examined using the SPDB Viewer (http://us.expasy.org/ spdbv/).
Statistical Analysis
Allele or genotype frequency differences between the African and European populations were determined using a w 2 test. Significant differences from Hardy-Weinberg equilibrium were calculated using Clump software. 46 Linkage disequilibrium between the polymorphisms within CDA, DCK, SLC28A1 and TYMS was calculated as D 0 , using the Polymorphism and Haplotype Analysis Suite. 30 
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